Oruka Therapeutics, Inc. (ORKA) — Market Cap, Revenue, Net Income, P/E

Oruka Therapeutics, Inc. ORKA

$67.89

▲ +2.07% 24H

About

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications. Its lead product, ORKA-001, targets the p19 subunit of interleukin-23 and is in Phase 2 trials for moderate-to-severe psoriasis, featu…

SectorHealthcare

ExchangeNASDAQ

IndustryBiotechnology

CountryUnited States

Employees28

TickerORKA

Statistics

Market Cap$3.41B

Revenue (TTM)—

Net Income-$105.4M

Net Margin—

EPS—

P/E-37.98

P/S—

P/B6.87

EV/EBITDA-27.40

ROE-27.3%

Dividend Yield—

Price$67.89

Data: Twelve Data · Revenue = mcap / P/S